SRL
ESPR

Scientech Research LLC’s Esperion Therapeutics ESPR Stock Holding History

Scientech Research LLC’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,009
Closed -$90.4K – 336
2026
Q1 		$90.4K Buy
33,009
+3,163
+11% +$10K 0.08% 347
2025
Q4 		$110K Buy
+29,846
New +$96.4K 0.07% 398

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Scientech Research LLC's ESPR Position: Q2 2026 in Review

Scientech Research LLC sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 33,009 shares — an estimated $90.4K sold.

Scientech Research LLC first reported a position in ESPR in Q4 2025 and held it in 2 quarters. The position peaked at $110K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Scientech Research LLC reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Scientech Research LLC sold 33,009 Esperion Therapeutics shares in Q2 2026, an estimated $90.4K.
  • Scientech Research LLC first reported a position in Esperion Therapeutics in Q4 2025 and held it in 2 quarters.
  • Scientech Research LLC's Esperion Therapeutics position peaked at $110K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Scientech Research LLC's 13F filing for Q2 2026, filed 14 Aug 2026.